LIVIVO - Search results -

Search results

Result 1 - 10 of total 31

Search options

Article ; Online: Successful Treatment of an Aggressive Adult T-cell Leukemia/Lymphoma with Strong CD30 Expression Using Brentuximab Vedotin as Combination and Maintenance Therapy.

Baba, Yuta / Sakai, Hirotaka / Kabasawa, Nobuyuki / Harada, Hiroshi

2022 Volume 62, Issue 4, Page(s) 613–616

Abstract: Adult T-cell leukemia/lymphoma (ATL) is a highly aggressive malignant tumor associated with a poor prognosis. We herein report a 63-year-old man who was newly diagnosed with aggressive ATL. He was treated with brentuximab vedotin (BV) plus ... ...

Abstract	Adult T-cell leukemia/lymphoma (ATL) is a highly aggressive malignant tumor associated with a poor prognosis. We herein report a 63-year-old man who was newly diagnosed with aggressive ATL. He was treated with brentuximab vedotin (BV) plus cyclophosphamide, doxorubicin, and prednisone (A+CHP therapy), along with intrathecal chemotherapy using methotrexate and cytarabine. After achieving remission, he was placed on maintenance therapy with BV in the outpatient setting every 21 days for 17 months, without relapse. We suggest that initial treatment with A+CHP therapy and BV maintenance therapy may be beneficial against strongly CD30-expressing ATL.
MeSH term(s)	Adult ; Male ; Humans ; Middle Aged ; Brentuximab Vedotin/therapeutic use ; Immunoconjugates/therapeutic use ; Leukemia-Lymphoma, Adult T-Cell/drug therapy ; Cyclophosphamide/therapeutic use ; Lymphoma/drug therapy
Chemical Substances	Brentuximab Vedotin (7XL5ISS668) ; Immunoconjugates ; Cyclophosphamide (8N3DW7272P)
Language	English
Publishing date	2022-07-22
Publishing country	Japan
Document type	Case Reports ; Journal Article
ZDB-ID	32371-8
ISSN	1349-7235 ; 0021-5120 ; 0918-2918
ISSN (online)	1349-7235
ISSN	0021-5120 ; 0918-2918
DOI	10.2169/internalmedicine.9812-22
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 240: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Successful Treatment of Immune Thrombocytopenic Purpura with Intracranial Hemorrhaging and Duodenal Bleeding Following SARS-CoV-2 Vaccination.

Baba, Yuta / Sakai, Hirotaka / Kabasawa, Nobuyuki / Harada, Hiroshi

Internal medicine (Tokyo, Japan)

2022 Volume 61, Issue 12, Page(s) 1891–1895

Abstract: Several vaccines have been developed for coronavirus disease 2019 - caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - in record time. A few cases of immune thrombocytopenic purpura (ITP) following SARS-CoV-2 vaccination have ... ...

Abstract	Several vaccines have been developed for coronavirus disease 2019 - caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - in record time. A few cases of immune thrombocytopenic purpura (ITP) following SARS-CoV-2 vaccination have been reported. We herein report a 90-year-old man who received the Pfizer-BioNTech SARS-CoV-2 vaccine (BNT162b2) and developed severe thrombocytopenia with intracranial hemorrhaging and duodenal bleeding, consistent with vaccine-related ITP. He was successfully treated with intravenous immunoglobulin, prednisolone, and eltrombopag and discharged without cytopenia. Vaccine-related ITP should be suspected in patients presenting with abnormal bleeding or purpura after vaccination.
MeSH term(s)	Aged, 80 and over ; BNT162 Vaccine/adverse effects ; COVID-19 ; Humans ; Intracranial Hemorrhages/chemically induced ; Intracranial Hemorrhages/drug therapy ; Male ; Purpura, Thrombocytopenic, Idiopathic/chemically induced ; Purpura, Thrombocytopenic, Idiopathic/drug therapy ; Thrombocytopenia/chemically induced ; Thrombocytopenia/drug therapy ; Vaccination/adverse effects
Chemical Substances	BNT162 Vaccine (N38TVC63NU)
Language	English
Publishing date	2022-04-09
Publishing country	Japan
Document type	Case Reports ; Journal Article
ZDB-ID	32371-8
ISSN	1349-7235 ; 0021-5120 ; 0918-2918
ISSN (online)	1349-7235
ISSN	0021-5120 ; 0918-2918
DOI	10.2169/internalmedicine.9199-21
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 240: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Extranodal NK/T-cell lymphoma in a unilateral adrenal tumor.

Baba, Yuta / Sakai, Hirotaka / Abe, Maasa / Kabasawa, Nobuyuki

Japanese journal of clinical oncology

2022 Volume 52, Issue 12, Page(s) 1450–1451

MeSH term(s)	Humans ; Lymphoma, Extranodal NK-T-Cell/diagnostic imaging ; Lymphoma, Extranodal NK-T-Cell/pathology ; Adrenal Gland Neoplasms/diagnostic imaging ; Adrenal Gland Neoplasms/surgery
Language	English
Publishing date	2022-08-22
Publishing country	England
Document type	Journal Article
ZDB-ID	190978-2
ISSN	1465-3621 ; 0368-2811
ISSN (online)	1465-3621
ISSN	0368-2811
DOI	10.1093/jjco/hyac134
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1298: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Chronic neutrophilic leukemia preceded by myelodysplastic syndromes.

Baba, Yuta / Nakamaki, Tsuyoshi / Sakai, Hirotaka / Fukuchi, Kunihiko / Kabasawa, Nobuyuki / Hattori, Norimichi / Harada, Hiroshi

International journal of hematology

2023 Volume 118, Issue 5, Page(s) 636–641

Abstract: Chronic neutrophilic leukemia (CNL) is primarily diagnosed by excluding myelodysplastic syndromes (MDS). We report the case of a patient who developed secondary CNL 3 years after hypoplastic MDS. We used droplet digital polymerase chain reaction mutation ...

Abstract	Chronic neutrophilic leukemia (CNL) is primarily diagnosed by excluding myelodysplastic syndromes (MDS). We report the case of a patient who developed secondary CNL 3 years after hypoplastic MDS. We used droplet digital polymerase chain reaction mutation detection assay to analyze genomic alterations during the progression from MDS to CNL. At the time of MDS diagnosis, U2AF1 Q157P and SETBP1 D868N were dominant and additional mutation of ASXL1 1934_insG was observed. CSF3R T618I and SETBP1 D868N were increasing at the time of CNL diagnosis. We revealed the accumulation of multiple gene mutations during CNL development from MDS. This suggests that CNL was clonally developed from the founding clone of MDS and CSF3R mutation contributes to the development of CNL in the present case. These findings provide insights into the pathology of CNL.
MeSH term(s)	Humans ; Leukemia, Neutrophilic, Chronic/complications ; Leukemia, Neutrophilic, Chronic/genetics ; Leukemia, Neutrophilic, Chronic/diagnosis ; Myelodysplastic Syndromes/complications ; Myelodysplastic Syndromes/genetics ; Mutation
Language	English
Publishing date	2023-07-13
Publishing country	Japan
Document type	Case Reports ; Journal Article
ZDB-ID	1076875-0
ISSN	1865-3774 ; 0917-1258 ; 0925-5710
ISSN (online)	1865-3774
ISSN	0917-1258 ; 0925-5710
DOI	10.1007/s12185-023-03636-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 269: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Efficacy of Venetoclax and Azacitidine in Acute Myeloid Leukemia Compared to Azacitidine Monotherapy: Real-World Experience.

Baba, Yuta / Hida, Noriko / Sambe, Takehiko / Abe, Maasa / Kabasawa, Nobuyuki / Sakai, Hirotaka / Yoshimura, Kiyoshi / Fukuda, Tetsuya

Anticancer research

2024 Volume 44, Issue 5, Page(s) 2003–2007

Abstract: Background/aim: The combination of venetoclax (VEN) and azacitidine (AZA) (VEN+AZA) leads to higher complete remission rates and longer overall survival (OS) in patients with untreated acute myeloid leukemia (AML) who are ineligible for intensive ... ...

Abstract	Background/aim: The combination of venetoclax (VEN) and azacitidine (AZA) (VEN+AZA) leads to higher complete remission rates and longer overall survival (OS) in patients with untreated acute myeloid leukemia (AML) who are ineligible for intensive combination chemotherapy. In practice, the doses of VEN and AZA are reduced at the attending physician's discretion to avoid adverse events; however, the impact of dose and duration reductions has not been fully clarified. We analyzed whether the efficacy was maintained with reduced VEN+AZA compared to AZA monotherapy in the real world. Patients and methods: A total of 33 patients were included; 17 (10 newly diagnosed, 7 primary refractory or relapsed) received VEN+AZA, and 16 (7 newly diagnosed, 9 primary refractory or relapsed) received AZA. We analyzed complete remission (CR) and CR with incomplete hematologic recovery (CRi) rates, OS, and the incidence of adverse events. Results: CR/CRi were achieved in 7/17 (41.2%) and 11/17 (64.7%) patients in the VEN+AZA group and 0/15 (0%) and 2/15 (6.7%) patients in the AZA group, respectively. The CR/CRi rate was higher in the VEN+AZA group than in the AZA group (p=0.001). OS was longer in the VEN+AZA group than in the AZA group (p=0.03), with a median of 506 days [95% confidence interval (CI)=234-585 days] and 208 days (95% CI=52-343 days), respectively. Conclusion: The doses of the VEN+AZA combination were reduced at the attending physician's discretion, resulting in a higher CR/CRi rate and longer OS than AZA monotherapy and is considered useful for AML in the real world.
MeSH term(s)	Humans ; Azacitidine/therapeutic use ; Azacitidine/adverse effects ; Azacitidine/administration & dosage ; Leukemia, Myeloid, Acute/drug therapy ; Leukemia, Myeloid, Acute/mortality ; Male ; Bridged Bicyclo Compounds, Heterocyclic/therapeutic use ; Bridged Bicyclo Compounds, Heterocyclic/administration & dosage ; Bridged Bicyclo Compounds, Heterocyclic/adverse effects ; Female ; Aged ; Sulfonamides/therapeutic use ; Sulfonamides/administration & dosage ; Sulfonamides/adverse effects ; Middle Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Aged, 80 and over ; Treatment Outcome ; Remission Induction ; Adult
Chemical Substances	Azacitidine (M801H13NRU) ; venetoclax (N54AIC43PW) ; Bridged Bicyclo Compounds, Heterocyclic ; Sulfonamides
Language	English
Publishing date	2024-04-27
Publishing country	Greece
Document type	Journal Article ; Comparative Study
ZDB-ID	604549-2
ISSN	1791-7530 ; 0250-7005
ISSN (online)	1791-7530
ISSN	0250-7005
DOI	10.21873/anticanres.17003
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1642: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: A case of blood triglyceride increased induced by ABVD therapy for classical Hodgkin lymphoma.

Yonezawa, Ryo / Shimamoto, Kazushi / Kabasawa, Nobuyuki / Sano, Mizuki / Tanaka, Shizuko / Matsui, Mitsuki / Harada, Hiroshi / Sunaga, Tomiko

Leukemia research reports

2023 Volume 19, Page(s) 100365

Abstract: There are no reports of blood triglyceride (TG) levels increasing with the ABVD regimen. Herein, we present a case of Hodgkin's lymphoma that exhibited ABVD-induced blood TG increase. The patient was a 40-year-old Japanese man. Empiric therapy was ... ...

Abstract	There are no reports of blood triglyceride (TG) levels increasing with the ABVD regimen. Herein, we present a case of Hodgkin's lymphoma that exhibited ABVD-induced blood TG increase. The patient was a 40-year-old Japanese man. Empiric therapy was initiated using the ABVD regimen for Hodgkin lymphoma. On day 58, the fasting blood TG concentration increased to 1,451 mg/dL. Since no adverse events were noted, 0.2 mg/day of pemafibrate was administered, and the ABVD regimen was continued. Blood TG levels should be periodically monitored during ABVD administration for the patients who are at high risk of increased blood TG levels.
Language	English
Publishing date	2023-02-25
Publishing country	England
Document type	Case Reports
ZDB-ID	2706248-X
ISSN	2213-0489
ISSN	2213-0489
DOI	10.1016/j.lrr.2023.100365
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Pretransplantation Inflammatory and Nutritional Status in Elderly Allogeneic Hematopoietic Stem Cell Transplantation: Prognostic Value of C-Reactive Protein-to-Albumin Ratio.

Miyazaki, Takuya / Tachibana, Takayoshi / Suzuki, Taisei / Izumi, Akihiko / Fujimaki, Katsumichi / Sato, Shuku / Tamai, Yotaro / Michishita, Yusuke / Suzuki, Takahiro / Ishii, Ryuji / Hirasawa, Akira / Hashimoto, Chizuko / Kabasawa, Nobuyuki / Inoue, Yasuyuki / Ishiyama, Taijiro / Yamamoto, Koh / Kanamori, Heiwa / Tanaka, Masatsugu / Nakajima, Hideaki

Transplantation and cellular therapy

2024 Volume 30, Issue 4, Page(s) 400.e1–400.e9

Abstract: There are no clear criteria for selecting elderly patients with hematologic malignancies eligible for allogeneic hematopoietic stem cell transplantation (HSCT). This study aimed to evaluate inflammatory and nutritional status biomarkers as prognostic ... ...

Abstract	There are no clear criteria for selecting elderly patients with hematologic malignancies eligible for allogeneic hematopoietic stem cell transplantation (HSCT). This study aimed to evaluate inflammatory and nutritional status biomarkers as prognostic indicators of allogeneic HSCT in elderly patients. We compared the prognostic effects of 4 representative pretransplantation biomarkers: C-reactive protein-to-albumin ratio (CAR), Glasgow Prognostic Score (GPS), prognostic nutritional index (PNI), and albumin-to-globulin ratio (AGR). A total of 143 patients age ≥60 years who underwent their first allogeneic HSCT for a hematologic malignancy were enrolled between 2010 and 2020 in our single-center cohort. The median patient age was 65 years (range, 60 to 72 years). Pretransplantation high CAR, high GPS, and low PNI scores were associated with poor overall survival (OS), but the AGR was not associated with OS. Among the 4 biomarkers, CAR stratified OS most significantly (P < .001). Multivariate analyses identified only high CAR as an independent prognostic factor associated with OS (hazard ratio [HR], 1.98; P = .031) and showed that a Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) score ≥3 also was associated with OS (HR, 2.04; P = .012). High CAR was correlated with poor performance status, male sex, and high Disease Risk Index, but not with high HCT-CI score. When the patients were stratified into 3 groups according to a composite risk assessment using CAR and HCT-CI, the 3-year OS decreased significantly with increasing scores (82.8%, 50.3%, and 27.0%, respectively; P < .0001). In conclusion, CAR is the most useful prognostic indicator among the inflammatory and nutritional status biomarkers for allogeneic HSCT in elderly patients. Inflammatory and nutritional status in the elderly may be important prognostic factors for allogeneic HSCT independent of HCT-CI score.
MeSH term(s)	Aged ; Humans ; Biomarkers ; C-Reactive Protein/analysis ; C-Reactive Protein/chemistry ; Hematologic Neoplasms/therapy ; Hematopoietic Stem Cell Transplantation/adverse effects ; Nutritional Status ; Prognosis ; Retrospective Studies ; Transplantation, Homologous/adverse effects ; Serum Albumin/analysis ; Serum Albumin/chemistry ; Inflammation/diagnosis
Chemical Substances	Biomarkers ; C-Reactive Protein (9007-41-4) ; Serum Albumin
Language	English
Publishing date	2024-01-20
Publishing country	United States
Document type	Journal Article
ZDB-ID	3062231-1
ISSN	2666-6367
ISSN (online)	2666-6367
DOI	10.1016/j.jtct.2024.01.068
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5082: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Antimicrobial Stewardship Program for Patients in the Hematological Department Receiving Carbapenem Therapy: A Single-Center and Interrupted Time Series Analysis.

Suzuki, Ayako / Yamaguchi, Fumihiro / Maeda, Masayuki / Hashiguchi, Miyuki / Kabasawa, Nobuyuki / Sasaki, Jun / Sato, Tokutada / Fuyama, Masaki / Yamazaki, Yohei / Endo, Kei / Iwata, Kae / Kobayashi, Sei / Fujihara, Hisato

Antibiotics (Basel, Switzerland)

2023 Volume 12, Issue 2

Abstract: As antibiotic resistance has become a global problem, the intervention of an antimicrobial stewardship team (AST) is warranted. In hematological disorders, infectious complications are crucial owing to abnormal neutrophil function and decreased cell- ... ...

Abstract	As antibiotic resistance has become a global problem, the intervention of an antimicrobial stewardship team (AST) is warranted. In hematological disorders, infectious complications are crucial owing to abnormal neutrophil function and decreased cell-mediated immunity. Despite the widespread implementation of AST intervention, the effectiveness of stewardship practices for immunocompromised patients remains uncertain. We determined the effect of AST interventions on carbapenem therapy in the department of hematology. Patients admitted to the department and undergoing carbapenem therapy were enrolled. We compared carbapenem use between the pre-AST (April 2016-March 2018) and post-AST (April 2018-March 2021) periods. Factors associated with long-term carbapenem therapy were investigated. Overall, 515 episodes of carbapenem therapy in 264 patients in the department were evaluated. According to the interrupted time series analysis, the number of days of therapy decreased with AST intervention (β = -0.263,
Language	English
Publishing date	2023-02-02
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2681345-2
ISSN	2079-6382
ISSN	2079-6382
DOI	10.3390/antibiotics12020302
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Usefulness of endoscopic ultrasound-guided fine needle aspiration for splenic parenchyma in patients suspected of having primary splenic malignant lymphoma.

Niiya, Fumitaka / Takano, Yuichi / Azami, Tetsushi / Kobayashi, Takahiro / Maruoka, Naotaka / Kabasawa, Nobuyuki / Harada, Hiroshi / Norose, Tomoko / Ohike, Nobuyuki / Nagahama, Masatsugu

Endoscopy international open

2021 Volume 9, Issue 1, Page(s) E96–E101

Abstract: Background and study ... ...

Abstract	Background and study aims
Language	English
Publishing date	2021-01-01
Publishing country	Germany
Document type	Journal Article
ZDB-ID	2761052-4
ISSN	2196-9736 ; 2364-3722
ISSN (online)	2196-9736
ISSN	2364-3722
DOI	10.1055/a-1287-9577
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Increased serum C-reactive protein is an adverse prognostic factor in low-risk myelodysplastic syndromes.

Baba, Yuta / Saito, Bungo / Shimada, Shotaro / Sasaki, Yohei / Fujiwara, Shun / Arai, Nana / Kawaguchi, Yukiko / Kabasawa, Nobuyuki / Tsukamoto, Hiroyuki / Uto, Yui / Yanagisawa, Kouji / Hattori, Norimichi / Harada, Hiroshi / Nakamaki, Tsuyoshi

International journal of hematology

2021 Volume 114, Issue 4, Page(s) 441–448

Abstract: Inflammatory cytokines play a role in hematopoiesis and development of myelodysplastic syndromes (MDS). Although increased serum levels of inflammatory cytokines are associated with poor survival in MDS patients, clinical management does not include ... ...

Abstract	Inflammatory cytokines play a role in hematopoiesis and development of myelodysplastic syndromes (MDS). Although increased serum levels of inflammatory cytokines are associated with poor survival in MDS patients, clinical management does not include assessment of inflammation. We investigated the significance of inflammation in MDS using serum C-reactive protein (CRP) levels, an indicator of the degree of systemic inflammation that can be used in routine practice. We hypothesized that serum CRP levels can be used to further classify low-risk MDS. We conducted a retrospective analysis of 90 patients with low-risk MDS, defined by the international prognostic scoring system (IPSS). We examined the prognostic relevance of CRP and known prognostic factors at diagnosis. Increased serum CRP (≥ 0.58 mg/dL) was associated with poor survival (hazard ratio [HR]: 17.63, 95% confidence interval [CI] 5.83-53.28, P < 0.001) both overall and among the 73 patients with low-risk MDS as defined by the revised IPSS (HR: 28.05, 95% CI 6.15-128.04, P < 0.001). Increased CRP might predict poor prognosis and serum CRP levels can indicate clonal hematopoiesis and non-hematological comorbidity in patients with low-risk MDS.
MeSH term(s)	Adult ; Aged ; Aged, 80 and over ; Biomarkers/blood ; C-Reactive Protein ; Comorbidity ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Myelodysplastic Syndromes/blood ; Myelodysplastic Syndromes/diagnosis ; Myelodysplastic Syndromes/mortality ; Prognosis ; ROC Curve ; Young Adult
Chemical Substances	Biomarkers ; C-Reactive Protein (9007-41-4)
Language	English
Publishing date	2021-07-05
Publishing country	Japan
Document type	Journal Article
ZDB-ID	1076875-0
ISSN	1865-3774 ; 0917-1258 ; 0925-5710
ISSN (online)	1865-3774
ISSN	0917-1258 ; 0925-5710
DOI	10.1007/s12185-021-03187-7
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 269: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito